The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Open accessAbstract
CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism. We here documented a fraction of CD11b+CD33+ myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small cell lung cancer (NSCLC) patients expressed surface ectonucleotidases CD39 and CD73. Tumor TGF-β stimulated CD39 and CD73 expression, thereby inhibited T cell and NK cell activity, and protected tumor cells from the cytotoxic effect of chemotherapy through ectonucleotidase activity. Mechanistically, TGF-β triggered phosphorylation of mammalian target of rapamycin, and subsequently activated hypoxia-inducible factor-1α (HIF-1α) that induced CD39/CD73 expression on MDSCs. CD39 and CD73 on MDSCs, therefore, link their immunosuppressive and chemo-protective effects to NSCLC progression, providing novel targets for chemo-immunotherapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Independent of glycolysis, the HIFs can induce the production of immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes such as ENTPD2/CD39L1, CD39, and CD73 (Table 1), which contribute to the multistep conversion of extracellular ATP through ADP/AMP to adenosine, thus promoting the maintenance of MDSCs, which limits the activity of immune checkpoint inhibitors”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [91]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D. J., Usheva, A., Erat, A., Chen, J., Enjyoji, K., Linden, J. M., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,613
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747
Kuang, D., Zhao, Q., Peng, C., Xu, J., Zhang, J., Wu, C. Y., & Zheng, L. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 930
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 857
Immune cell regulation by autocrine purinergic signalling
JUNGER, W. G. (2011) · Nature reviews. Immunology · doi:10.1038/nri2938 · Cited by 855
Zea, A. H., Rodrı́guez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D. F., Quiceno, D. G., Youmans, A. J., O’Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 852
Cited by
Sorted by citations
Items 201–299 of 299
Ma, S., Qin, L., Wang, X., Wang, W., Li, J., Wang, H., Li, H., Cai, X., Yang, Y., & Qu, M. (2022) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.6531 · Cited by 12
Self-citationReprogramming the immune microenvironment in lung cancer
Chen, K., Luo, L., Li, Y., & Ge, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1684889 · Cited by 11
Self-citationKim, J., Choi, J. Y., Min, H., & Hwang, K. W. (2024) · Immune Network · doi:10.4110/in.2024.24.e26 · Cited by 11
Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications
Luo, N., Chen, C., Zhou, W., Hao, J., He, S., Liu, Y., Ku, Y., Huang, L., Zhang, C., Shu, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70387 · Cited by 12
Self-citationTrypanosoma cruzi Induces Regulatory B Cell Alterations in Patients With Chronic Chagas Disease
Girard, M. C., Ossowski, M. S., Muñoz-Calderón, A. A., Fernandez, M. L., Hernández-Vásquez, Y., Chadi, R., & Gómez, K. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.723549 · Cited by 11
Degranulation of human mast cells: modulation by P2 receptors’ agonists
Schulman, E. S., Nishi, H., & Pelleg, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1216580 · Cited by 11
Antitumoral Action of Resveratrol Through Adenosinergic Signaling in C6 Glioma Cells
Sánchez-Melgar, A., Muñoz-López, S., Albasanz, J. L., & Martı́n, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.702817 · Cited by 11
CD39 abrogates platelet-derived factors induced IL-1β expression in the human placenta
Forstner, D., Guettler, J., Brugger, B. A., Lyssy, F., Neuper, L., Daxboeck, C., Cvirn, G., Fuchs, J., Kraeker, K., Frolova, A., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1183793 · Cited by 10
Xu, J.-G., Chen, S., He, Y., Zhu, X., Wang, Y., Ye, Z., Zhou, J. C., Wu, X., Zhang, L., Ren, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55207-9 · Cited by 11
Self-citationImmunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
Wei, Q., Zhang, L., Zhao, N., Cheng, Z., Hua, X., & Ding, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012927 · Cited by 10
Hajaj, E., Pozzi, S., & Erez, A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041538 · Cited by 10
Tumor hypoxia shapes natural killer cell anticancer activities
Retamal, M. A., Salazar‐Onfray, F., González, F. E., & Tittarelli, A. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02557-6 · Cited by 10
Moresi, F., Noto, F., Vasudevan, J., Bisteau, X., Adriani, G., & Pavesi, A. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500098 · Cited by 10
Boral, B., Ballı, H. T., Sözütok, S., Pehlivan, U. A., & Aikimbaev, K. S. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13132 · Cited by 9
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis
Ning, Z., Liu, K., Zhang, H., Dong, G., Wang, X., & Xiong, H. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02640-8 · Cited by 9
Ouyang, P., Lin, B., Du, J., Pan, H., Yu, H., He, R., & Huang, Z. (2018) · Gene · doi:10.1016/j.gene.2018.01.014 · Cited by 9
Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
Kong, F., Wang, Z., Liao, D., Zuo, J., Xie, H., Li, X., & Jia, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739191 · Cited by 9
Pattabiram, S., Gangadaran, P., Dhayalan, S., Chatterjee, G., Reyaz, D., Prakash, K., Arun, R., Rajendran, R. L., Ahn, B., & ArulJothi, K. N. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090730 · Cited by 11
Bauer, A., Gebauer, N., Knief, J., Tharun, L., Arnold, N., Riecke, A., Steinestel, K., & Witte, H. M. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04211-x · Cited by 8
Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?
Hamoud, A.-R. A., Bach, K., Kakrecha, O., Henkel, N., Wu, X., McCullumsmith, R. E., & O'Donovan, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911835 · Cited by 8
Advancing Immunotherapy in Pancreatic Cancer
Hegazi, A., Rager, L. E., Watkins, D., & Su, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111560 · Cited by 9
Decoding the complex web: cellular and molecular interactions in the lung tumour microenvironment
Issa, B. S., Adhab, A. H., Mahdi, M. S., Kyada, A., Ganesan, S., Bhanot, D., Naidu, K. S., Kaur, S., Mansoor, A. S., Radi, U. K., et al. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2445772 · Cited by 8
Lu, Y., Ma, Q., Tan, H., Li, X., Zhang, X., & Tie, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118751 · Cited by 8
Flati, I., Nolfi, M. D. V., Dall’Aglio, F., Vecchiotti, D., Verzella, D., Alesse, E., Capece, D., & Zazzeroni, F. (2023) · Genes · doi:10.3390/genes14101953 · Cited by 7
Gu, J., Chang, J., Chen, S., Zhi, H., Sun, J., Yin, W., Zhang, T., Zang, J., Zhao, Y., Liu, Y., et al. (2024) · Small Science · doi:10.1002/smsc.202300242 · Cited by 13
Self-citationAndo, T., Sakurai, K., Hoshi, M., Tezuka, H., Sakai, Y., Kato, T., & Ito, H. (2025) · Immunobiology · doi:10.1016/j.imbio.2025.153119 · Cited by 7
Meyer, A. V., Klein, D., de Leve, S., Szymonowicz, K., Stuschke, M., Robson, S. C., Jendrossek, V., & Wirsdörfer, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554883 · Cited by 7
Histone lactylation-derived TET2 enhanced Arg1-mediated MDSC immunosuppression
Da, W., Dai, Y., Shen, B., Zhang, Y., Bao, P., Zhu, W., Wang, D., Wang, S., & Ma, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677780 · Cited by 6
Self-citationAdvances in artificial metabzymes for macrophage polarization in tumor metabolic immunotherapy
Sun, L., Wang, J., Song, Q., Li, F., Ling, D., & Hu, X. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102962 · Cited by 6
Self-citationHan, W.-J., He, Z., Xing, J.-W., Zheng, B.-W., Liu, X., Liu, H., Liu, Y., Xiao, Y., & Luo, E. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124139 · Cited by 7
Myeloid-Derived Suppressor Cells: Implications in Cancer Immunology and Immunotherapy
Santibanez, J. F. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25203 · Cited by 8
Antitumor effects of targeting myeloid-derived suppressive cells
Zeng, D., Long, H., & Zhu, B. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.52 · Cited by 6
Molina-Castillo, G., Monroy-García, A., García‐Rocha, R., Weiss‐Steider, B., Montesinos, J. J., Hernández‐Montes, J., Don‐López, C. A., Castro-Manrreza, M. E., Escobar, M. L., & Mora‐García, M. D. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062413 · Cited by 5
Targeting the hypoxia signaling pathway with nanomedicine to reverse immunotherapy resistance
Cheng, X., Wang, P., Lyu, H., Lee, Y., Yoon, J., & Dong, H. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.132 · Cited by 5
Bharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 7
Xu, W., Ye, J., Cao, Z., Zhao, Y., Zhu, Y., & Li, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32357 · Cited by 6
Self-citation[Blocking Adenosine/A2AR Pathway for Cancer Therapy].
Liu, J., Shi, Y., Liu, X., Zhang, D., Bai, Y., Xu, Y., & Wang, M. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.24 · Cited by 5
Multifaceted role of myeloid-derived suppressor cells in colorectal cancer
Zhang, J., Lian, J., Li, N., Yueying, & Wu, G. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115274 · Cited by 6
Witte, H. M., Gebauer, N., & Steinestel, K. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103592 · Cited by 5
Adenosine Concentration Determination for in Vitro Tumor Microenvironment Simulation
Chen, C., Yang, C., Hu, S., Nie, W., Ye, S., Lu, M., Xu, X., & Hu, H. (2025) · Dose-Response · doi:10.1177/15593258251371484 · Cited by 4
CD39+MDSC Facilitates Cisplatin Resistance of Ovarian Cancer Cells by Affecting Adenosine Synthesis
Ma, J., Zhou, C., Zheng, X., & Chen, X. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128256397230920093628 · Cited by 4
Self-citationTandarić, L., Auranen, A., Kleinmanns, K., Christensen, R. D., Thomsen, L. C. V., Wogsland, C. E., McCormack, E., Maenpaa, J. U., Madsen, K., Petersson, K. S., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13811 · Cited by 4
Zhang, Q., Liu, Y., Xuan, H., Zhan, S., Shen, Y., Wang, R., Chen, S., Ding, S., Liu, C., Huang, L., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251380957 · Cited by 4
Self-citationA Review of Proteomics Strategies to Study T-Cell Activation and Function in Cancer Disease
Papale, M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1507-2_9 · Cited by 4
Xu, Z., Liu, K., Xu, Q., Li, P., Wu, Q., & Ye, J. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251382839 · Cited by 4
The microbiome: regulating anti-tumor immunity
Tao, Y.-L., Wu, X.-X., Wang, J.-R., Liu, M., Liu, Y.-N., Lian, Y.-Q., Liang, Z., & Zhu, S.-F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1781872 · Cited by 3
Foglia, B., Nurcis, J., Signorini, M., & Cannito, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1823145 · Cited by 3
Krumm, J., Petrova, E. P., Lechner, S., Mergner, J., Boehm, H.-H., Prestipino, A., Steinbrunn, D., Deline, M. L., Koetzner, L., Schindler, C., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100632 · Cited by 3
Wang, C., Feng, Q., Lu, H., He, Q., Zhang, P., Tang, J., Liu, Z., Liu, J., & Chen, B. (2024) · Materials Today Nano · doi:10.1016/j.mtnano.2024.100509 · Cited by 3
Myeloid-derived suppressor cells: Identification and function
Vacca, P., Bilotta, M. T., Moretta, L., & Tumino, N. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.07.009 · Cited by 3
Zhang, J., Späth, S. S., Weissman, S. M., & Katz, S. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_10 · Cited by 3
Biomarker-Driven Immunotherapy for Precision Medicine in Prostate Cancer
Ottini, A., Sepe, P., Beninato, T., Claps, M., Guadalupi, V., Verzoni, E., Giannatempo, P., Baciarello, G., de Braud, F., & Procopio, G. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0079 · Cited by 4
Haanen, J. B. A. G., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01112 · Cited by 3
DriverMP enables improved identification of cancer driver genes
Liu, Y., Han, J., Kong, T., Xiao, N., Mei, Q., & Liu, J. (2022) · GigaScience · doi:10.1093/gigascience/giad106 · Cited by 2
Peñate, L., Carrillo-Beltrán, D., Spichiger, C., Cuevas-Zhbankova, A., Torres, Á., Silva, P., Richter, H. G., Ayuso‐Sacido, Á., Martín, R. S., & Quezada-Monrás, C. (2024) · Pharmaceuticals · doi:10.3390/ph17050579 · Cited by 3
Deciphering hypoxia’s role in hepatocellular carcinoma prognosis with single-cell approaches
Liang, J., Chen, D., & Liang, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03201-y · Cited by 3
Ma, Y., Su, Y., Huang, J. Z., Zhao, W., Huang, C., Qin, J., You, S., Yan, H., & Ni, X. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02185-6 · Cited by 2
Self-citationde Oliveira, P. H. S., Silva-Freitas, B. B., Meyer‐Fernandes, J. R., & Lacerda‐Abreu, M. A. (2025) · Membranes · doi:10.3390/membranes15120381 · Cited by 2
Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells
Su, A., Tian, C.-Q., Ou, Y.-J., Bao, X., Huan, X., Miao, Z., & Wang, Y.-Q. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122129 · Cited by 2
Piqueras-Nebot, M., Benet, M., Estors, M., Cremades, A., Juan, Ó., Carretero, J., Galbis, J. M., & Lahoz, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-99877-x · Cited by 2
Portillo‐Miño, J. D., Calderón, J. J., Ruíz‐García, E., & Monge, C. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03960-8 · Cited by 3
Targeting Inhibitory Cells Such as Tregs and MDSCs in the Tuberculous Granuloma
Parveen, S., Murphy, J. R., & Bishai, W. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-56905-1_11 · Cited by 2
Rafei, H., Başar, R., Rezvani, K., & Daher, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00021-5 · Cited by 1
Joshi, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90012-2 · Cited by 1
Clostridioides difficile meets the adenosine system: the art of manipulating host homeostasis
Fettucciari, K., Cari, L., Spaterna, A., SORDO, R. D., Tavanti, F., Marconi, P., & Bassotti, G. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01160-8 · Cited by 1
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer
Mallikarjuna, P., Erdem, C., Hedman, H., Sitaram, R. T., Beorlegui, R. I., Aripaka, K., Larsson, A. O., Ljungberg, B., Kamali‐Moghaddam, M., & Landström, M. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02404-7 · Cited by 1
Chen, Y., Zhang, C., Yu, Z., Hu, K., & Zhou, T. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.168636 · Cited by 1
Kang, S.-B., Jeong, J. H., Kim, S. W., Yoo, H., Lee, S., Oh, J.-H., Sung, C. O., Lee, S.-H., Jun, E., & Jang, M. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201152 · Cited by 1
Molecular Targets for Cancer Immunotherapy: Focusing on (Immune and Tumor) Cell-Derived Metabolites
Quintans, R. D. T., de Freitas, Â. A., de Souza, M. M., Dias-Lopes, G., & Silva, R. C. M. C. (2026) · Applied Sciences · doi:10.3390/app16052461 · Cited by 1
Bauer, A., Arndt, A., Reichenbach, L. B., Gebauer, N., Müller, M. M., Neumann, C., Schulz, C., Steinestel, K., Heller, R. A., Chteinberg, E., et al. (2026) · Cancers · doi:10.3390/cancers18071087 · Cited by 1
Xu, Y., Xu, W., Zhang, W., Li, S., Zhang, D., Lin, X., Sun, Q., Wang, Y., Hu, P., & Si, H. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.03.062 · Cited by 1
Iravani, N. J., Majidzadeh‐A, K., Arab, S., Zarinfam, S., & Hasannejad, F. (2026) · Cancer Management and Research · doi:10.2147/cmar.s581878 · Cited by 1
Zhao, X.-P., Mai, C.-T., Zhao, Y., Zhou, X.-Y., Lai, N.-H., Zhang, X.-J., & Fan, X. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189590 · Cited by 1
Self-citationBi, C., Schwermer, F., Tang, L., Müller, C. E., & Liu, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00078 · Cited by 1
Qian, J., Ma, C., Waterbury, Q. T., Zhi, X., Moon, C. S., Tu, R., Kobayashi, H., Wu, F., Zheng, B., Zeng, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.09.617228 · Cited by 1
Sun, H., Kang, S., Wu, J., Li, X., Liu, Y., & Li, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2366378/v1
Self-citationCancer Traits; Present and Future
Asseri, K. A., & Aldahish, A. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080384123010005
[Research Progress of Granulocytic Myeloid-derived Suppressor Cells in Non-small Cell Lung Cancer].
Yang, C., Zhu, R., Zhang, Y., Ying, L., Wang, J., Liu, P., & Su, D. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.28
Self-citationCellular Immune Responses in Tumor Microenvironment
Khamaru, S., Tung, K. S., & Chattopadhyay, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-88695-9_1
Chronic inflammation induced immunosuppression
Greten, F. R., & Pesic, M. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00048-5
Rajak, J., Meng, K., Stippel, A. L., Wang, J., Koleci, N., Bohler, S., Schlaak, A. E., Xiao, H., Braun, L. M., Masetti, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.01.679664
Li, R., Zhao, A., Yan, C., Li, B., & Hao, Z. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003940
Liu, C., Yang, L., Xu, H., Zheng, S., Wang, Z., Wang, S., Yang, Y., Zhang, S., Feng, X., Sun, N., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19759695
Self-citationLiu, C., Yang, L., Xu, H., Zheng, S., Wang, Z., Wang, S., Yang, Y., Zhang, S., Feng, X., Sun, N., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19759701
Self-citationBalzasch, B. M., von Kries, A., Hüll, S., Shaltiël, I. A., Boonekamp, K. E., Ast, V., Burgermeister, E., Betge, J., Ebert, M., Boutros, M., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2633012
Zhao, C., Ning, X., Zhou, H., Li, G. L., Wu, X., & Li, L. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118728
Self-citationChen, A., Xie, D.-J., Jhu, Y., Lin, Y.-J., Wu, D.-Y., Yan, S.-L., Chou, Y., & Ko, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119281
Le rôle de deux alarmines extracellulaires, HMGB1 et l’ATP, dans le cadre du cancer colorectal
Dillard, C. (2021) · theses.fr (ABES) · doi:10.70675/51029938z640az4398za0f8z6a69fb660b30
Impact of respiratory viral infections on tumor progression in Non-Small-Cell Lung Carcinoma (NSCLC)
Angrini, M. (2021) · theses.fr (ABES) · doi:10.70675/9c027d88z3675z44adza870z1802353e674a
EVT-701 : targeting electron transport chain complex I as therapeutic approach in cancer
Yolba, R. L. (2021) · theses.fr (ABES) · doi:10.70675/9cadea77z03ccz4a54zb381zf34a432615a5
Mapping the immune microenvironment of non-small cell lung cancer
Ge, X., Cai, M., Nie, J., Wang, L., Li, Y., Hu, Y., Meng, J., Liu, H., Geng, L., 花宝金, et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105335
Self-citationJiang, M., Zhang, K., Zheng, X., Bo, Z., & Wei, R. (2026) · Cancer Biome and Targeted Therapy · doi:10.66505/cbtt.v1i2.17
Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation
Zhang, Q., Yuan, C., Zhu, L., Zheng, S., Xu, Y., 车炫霖, Xiao, S., Liu, J., Hong, L., Li, H., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02694-7
Self-citationThe CD73-adenosine axis in melanoma: from multidimensional regulation to precision immunotherapy
Liu, X., Sun, P., Chen, C., & Chen, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1839832
Self-citationO 2 -sensing and HIF regulation: from oxygen homeostasis to tumor-associated immune responses
Schneider, V., Fandrey, J., & Winning, S. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00185.2026
Li, R., Li, S., & Zhang, T. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1915472
Monocyte inflammation and adaptive immune dysfunction in severe Klebsiella pneumoniae pneumonia
Chen, H., Wang, X., Liu, X., Dong, K., Feng, Y., Yuan, M., Wang, S., Fan, F.-F., Tian, Y., Kang, Z., et al. (2026) · iMeta · doi:10.1002/imt2.70172
Self-citation
Metadata
- Authors
- Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., Li, F., Yang, L., Huang, J., Yang, S., Li, H., Zhao, X., Dong, W., Yan, Y., Zhao, S., Huang, B., Zhang, B., & Zhang, Y.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Northwestern University (US)
- Corresponding author
- Wang, Liping
- Zhang, Bin
- Zhang, Yi
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-05-30
- Volume
- 6
- Issue
- 6
- Pages
- e1320011-e1320011
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5486179
- OpenAlex
- W2605835842
- Cited by
- 299
- References
- 57
- Citations by year
- 2026: 22 · 2025: 32 · 2024: 33 · 2023: 33 · 2022: 52 · 2021: 45 · 2020: 37 · 2019: 26 · 2018: 19
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81171985, 112300410153, 122300410155, 81171986, 20110110001)
- Science and Technology Department of Henan Province
- National Institutes of Health (CA149669)
- National Cancer Institute (R01CA208354)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- CD39/CD73, myeloid-derived suppressor cells, non-small cell lung cancer, TGF-beta, mTOR, HIF-1α, adenosine pathway, ectonucleotidases, tumor immunosuppression, chemoresistance, T cell suppression, NK cell inhibition, chemoimmunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
